Clinical Trials (PDQ®)
|Phase II, Phase I||Treatment||Active||1 to 21||Other||T2008-002|
Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.
- Patients to be enrolled in the dose-escalation portion of this study must have T-cell ALL or T-cell lymphoblastic lymphoma (LL) in first relapse or must have failed primary induction chemotherapy (ie, never attained a complete remission following an initial course of standard therapy for T-ALL or T-LL). Patients to be enrolled in the cohort expansion portion of this study (ie, those treated at the recommended phase 2 dose) must have T-cell ALL in first relapse or must have failed primary induction chemotherapy (ie, never attained a complete remission following an initial course of standard therapy for T-ALL). T-LL patients are not eligible for the cohort expansion phase.
- Patients with T-cell ALL must have greater than 25% blasts in the bone marrow with or without extramedullary disease.
- Patients with T-cell LL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis. Patients with T-cell LL enrolled in the phase I dose-escalation study are not required to have measurable disease; however, patients enrolled in the phase II cohort expansion at the MTD must have measurable disease.
- Patients may have CNS 1 or CNS 2 disease but not CNS 3.
- ECOG 0-2 or Karnofsky ≥ 50% for patients > 16 years of age; Lansky ≥ 50% for patients ≤16 years of age.
- Patients may be enrolled on study regardless of the timing of prior Intrathecal therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF 7 DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY.
- At least 6 weeks must have elapsed since administration of nitrosureas.
- At least 12 weeks must have elapsed since administration of craniospinal or hemipelvic radiation.
- Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
- Female patients with infants must agree not to breastfeed their infants while on this study.
- Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.
- Adequate renal function defined as serum creatinine ≤ 1.5x upper limit of normal (ULN) for age. If the serum creatinine is above these values, the calculated creatinine clearance or radioisotope GFR must be ≥ 70 mL/min/1.73m2.
- Total bilirubin ≤ 1.5x ULN for age. If the total bilirubin is elevated, patient will still be eligible if the conjugated (direct) serum bilirubin ≤ ULN for age.
- ALT ≤ 5x ULN of normal for age.
- Adequate cardiac function defined as shortening fraction of ≥ 27% by echocardiogram or ejection fraction ≥ 45% by gated radionuclide study.
- No evidence of dyspnea at rest
- No exercise intolerance
- A pulse oximetry ≥ 94% at sea level (≥ 90% at altitude ≥ 5000 feet) if there is clinical indication for determination.
- Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent.
- Patients with Down syndrome are excluded.
- Patients with pre-existing Grade 2 (or greater) peripheral motor or sensory neurotoxicity per the CTCAE 3.0 as determined by the treating physician or a neurologist.
- Patients with a history of prior veno-occlusive disease (VOD) or findings consistent with a diagnosis of VOD, defined as: conjugated serum bilirubin >1.4 mg/dL AND unexplained weight gain greater than 10% of baseline weight or ascites AND hepatomegaly or right upper quadrant pain without another explanation, OR reversal of portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy.
- Previous hematopoetic stem cell transplantation.
- Patients with a prior seizure disorder requiring anti-convulsant therapy are not eligible to receive nelarabine. For the purposes of this study, this includes any patient that has received anticonvulsant therapy to prevent/treat seizures in the prior two years.
- Positive blood culture within 48 hours of study enrollment.
- Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection.
- Plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
- Any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
Trial Lead Organizations/Sponsors
Therapeutic Advances in Childhood Leukemia ConsortiumGlaxoSmithkline
|Jim Whitlock, MD||Study Chair|
|Jeannette van der Giessen, BA||Ph: 323-361-8725|
|Children's Hospital Los Angeles|
|Paul S. Gaynon||Principal Investigator|
|Children's Hospital of Orange County|
|UCSF Helen Diller Family Comprehensive Cancer Center|
|Steven DuBois||Principal Investigator|
|Children's Hospital Colorado Center for Cancer and Blood Disorders|
|Lia Gore||Principal Investigator|
|District of Columbia|
|Children's National Medical Center|
|University of Miami Sylvester Comprehensive Cancer Center - Miami|
|John Goldberg, MD||Principal Investigator|
|Winship Cancer Institute of Emory University|
|Ann and Robert H. Lurie Children's Hospital of Chicago|
|Nobuko Hijiya, MD||Principal Investigator|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute|
|C.S. Mott Children's Hospital at University of Michigan Medical Center|
|Raymond J. Hutchinson||Principal Investigator|
|Children's Hospitals and Clinics of Minnesota - Minneapolis|
|Bruce C. Bostrom||Principal Investigator|
|Yoav Messinger||Principal Investigator|
|Children's Mercy Hospital|
|Kathleen Neville, MD||Principal Investigator|
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center|
|Julia L. Glade-Bender||Principal Investigator|
|NYU Cancer Institute at New York University Medical Center|
|Elizabeth A. Raetz||Principal Investigator|
|Levine Children's Hospital|
|Javier Oesterheld, MD|
|Javier Oesterheld, MD||Principal Investigator|
|Joe Matloub, MD|
|Nationwide Children's Hospital|
|Knight Cancer Institute at Oregon Health and Science University|
|St. Jude Children's Research Hospital|
|Deepa Bhojwani, MD|
|Vanderbilt Children's Hospital|
|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas|
|Cook Children's Hospital|
|Ken Heym, MD|
|Salt Lake City|
|Primary Children's Medical Center|
|Elizabeth Raetz, MD|
|Children's Hospital and Regional Medical Center - Seattle|
|Blythe Thompson, MD||Principal Investigator|
|Medical College of Wisconsin Cancer Center|
|Mike Burke, MD|
|New Childrens Hospital|
|Children's Hospital at Westmead|
|Royal Children's Hospital|
|Royal Children's Hospital, Melbourne|
|St. Anna Children's Hospital|
|Andische Attarbaschi, MD, PhD|
|Children's and Women's Hospital of British Columbia|
|Sainte Justine University Hospital|
|Henrique Bittencourt, MD|
|Brigitte Nelken, MD, Phd|
|Bambino Gesù Hospital|
|Franco Locatelli, MD, PhD|
|Erasmus MC - Sophia|
|Michel Zwaan, MD, PhD|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00981799
ClinicalTrials.gov processed this data on February 27, 2015
Back to Top